| A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions M Damelin, A Bankovich, J Bernstein, J Lucas, L Chen, S Williams, A Park, ... Science translational medicine 9 (372), eaag2611, 2017 | 136 | 2017 |
| Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions M Damelin, A Bankovich, A Park, J Aguilar, W Anderson, M Santaguida, ... Clinical cancer research 21 (18), 4165-4173, 2015 | 78 | 2015 |
| Liver microvascular injury and thrombocytopenia of antibody–calicheamicin conjugates in cynomolgus monkeys—mechanism and monitoring M Guffroy, H Falahatpisheh, K Biddle, J Kreeger, L Obert, K Walters, ... Clinical Cancer Research 23 (7), 1760-1770, 2017 | 51 | 2017 |
| PF-06804103, a site-specific anti-HER2 antibody–drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers EI Graziani, M Sung, D Ma, B Narayanan, K Marquette, S Puthenveetil, ... Molecular cancer therapeutics 19 (10), 2068-2078, 2020 | 40 | 2020 |
| Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape E Tarcsa, MR Guffroy, H Falahatpisheh, C Phipps, JC Kalvass Drug Discovery Today: Technologies 37, 13-22, 2020 | 28 | 2020 |
| Anti-extra domain B splice variant of fibronectin antibody–drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade AT Hooper, K Marquette, CPB Chang, J Golas, S Jain, MH Lam, M Guffroy, ... Molecular Cancer Therapeutics 21 (9), 1462-1472, 2022 | 11 | 2022 |
| Improving the safety profile of ADCs M Guffroy, H Falahatpisheh, M Finkelstein Innovations for next-generation antibody-drug conjugates, 45-71, 2018 | 6 | 2018 |
| A PTK7-targeted antibodydrug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017; 9: eaag2611 M Damelin, A Bankovich, J Bernstein, J Lucas, L Chen, S Williams, A Park, ... | 5 | |
| Anatomic and clinical pathology characterization of drug-induced sinusoidal obstruction syndrome (veno-occlusive disease) in cynomolgus macaques R Kohnken, H Falahatpisheh, KS Janardhan, M Guffroy Toxicologic Pathology 50 (1), 13-22, 2022 | 4 | 2022 |
| Next-generation DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies MC Jarvis, G Mittapalli, E Creger, C Nora, M Ibanez, D Bhat, B Hofilena, ... Cancer Research 83 (7_Supplement), 5019-5019, 2023 | 2 | 2023 |
| An anti-Ephrin-A4 calicheamicin conjugate effectively targets triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regression M Damelin, A Bankovich, A Park, J Aguilar, W Anderson, M Santaguida, ... Cancer Research 75 (15_Supplement), 5425-5425, 2015 | 1 | 2015 |
| Abstract P250: Evaluation of systemic pan-CLK/DYRK inhibition on organ function and tissue self-renewal H Falahatpisheh, M Dehghani, J Morrow, C Tsao, S Dorrow, J Stewart, ... Molecular Cancer Therapeutics 20 (12_Supplement), P250-P250, 2021 | | 2021 |
| Development of Antibody-Drug Conjugates 1 SA Roberts, S Chivers, A Connor, H Falahatpisheh, M Guffroy, AJ Lee, ... Translational Medicine, 277-304, 2021 | | 2021 |
| CAN THE HIGHEST NON-SEVERELY TOXIC DOSE FOR PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATES IN CYNOMOLGUS MONKEY PREDICT HUMAN MAXIMUM-TOLERATED DOSE?. R Menon, L Loberg, J Tibbitts, H Falahatpisheh, K Marsh, B Philip, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S48-S49, 2020 | | 2020 |
| Antibody-drug conjugates as targeted therapies: Are we there yet E Tarcsa, MR Guffroy, H Falahatpisheh, C Phipps, JC Kalvass A critical review of the current clinical landscape. Drug Discovery Today …, 2020 | | 2020 |
| Abstract LB-202: Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates: mechanism and monitoring M Guffroy, H Falahatpisheh, K Biddle, J Kreeger, L Obert, K Walters, ... Cancer Research 76 (14_Supplement), LB-202-LB-202, 2016 | | 2016 |
| A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions MI Damelin, A Bankovich, J Bernstein, J Lucas, L Chen, S Williams, ... Cancer Research 76 (14_Supplement), 1220-1220, 2016 | | 2016 |
| Journal Clinical Cancer Research M Guffroy, H Falahatpisheh, K Biddle, J Kreeger, L Obert, K Walters, ... | | |
